Experience with imatinib mesylate in children with Ph+ chronic myelogenous leukemia

被引：0
|
作者：
Kapoor, Gauri [1 ]
Abedin, Sarfrazu [1 ]
Garg, Pravesh [1 ]
Tyagi, Vinod [1 ]
Khullar, Paras [1 ]
机构：
[1] Rajiv Gandhi Canc Inst & Res Ctr, Delhi, India
来源：
PEDIATRIC BLOOD & CANCER | 2007年 / 49卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：528 / 528
页数：1
相关论文
共 50 条
  • [41] Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase
    Warren, E
    Ward, S
    Gordois, A
    Scuffham, P
    CLINICAL THERAPEUTICS, 2004, 26 (11) : 1924 - 1933
  • [42] Successful imatinib mesylate therapy for acquired von Willebrand syndrome in chronic myelogenous leukemia
    Uchiyama, Michihiro
    Ikeda, Takashi
    LEUKEMIA RESEARCH, 2009, 33 (12) : 1723 - 1724
  • [43] Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia
    Donato, NJ
    Wu, JY
    Stapley, J
    Lin, H
    Arlinghaus, R
    Aggarwal, B
    Shishodin, S
    Albitar, M
    Hayes, K
    Kantarjian, H
    Talpaz, M
    CANCER RESEARCH, 2004, 64 (02) : 672 - 677
  • [44] Severe bone marrow aplasia following imatinib mesylate in a patient with chronic myelogenous leukemia
    Lokeshwar, N
    Kumar, L
    Kumari, M
    LEUKEMIA & LYMPHOMA, 2005, 46 (05) : 781 - 784
  • [45] Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia
    Bueso-Ramos, CE
    Cortes, J
    Talpaz, M
    O'Brien, S
    Giles, F
    Rios, MB
    Medeiros, LJ
    Kantarjian, H
    CANCER, 2004, 101 (02) : 332 - 336
  • [46] Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation
    Millot, F
    Guilhot, J
    Nelken, B
    Leblanc, T
    De Bont, ES
    Békassy, AN
    Gadner, H
    Sufliarska, S
    Stary, J
    Gschaidmeier, H
    Guilhot, F
    Suttorp, M
    LEUKEMIA, 2006, 20 (02) : 187 - 192
  • [47] Gastric Antral Vascular Ectasia during the Treatment of Chronic Myelogenous Leukemia with Imatinib Mesylate
    Narukawa, Kensuke
    Kakihana, Kazuhiko
    Fujiwara, Takashi
    Kobayashi, Takeshi
    Doki, Noriko
    Sakamaki, Hisashi
    Ohashi, Kazuteru
    INTERNAL MEDICINE, 2016, 55 (01) : 69 - 72
  • [48] Physiologic Hypoxia Protects Chronic Myelogenous Leukemia Progenitors From Elimination by Imatinib Mesylate
    Ng, King-Pan
    Poh, Tuang Yeow
    Sun, Wen Tian
    Chuah, Charles
    Ong, S. Tiong
    BLOOD, 2009, 114 (22) : 858 - 858
  • [49] Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia
    Sureda, A
    Carrasco, M
    de Miguel, M
    Martínez, JA
    Conde, E
    Sanz, MA
    Díaz-Mediavilla, J
    Sierra, J
    HAEMATOLOGICA, 2003, 88 (11) : 1213 - 1220
  • [50] Changes from imatinib mesylate to second generation tyrosine kinase inhibitors improve renal impairment with imatinib mesylate in chronic myelogenous leukemia
    Akihisa Hino
    Hitoshi Yoshida
    Yuma Tada
    Midori Koike
    Ryota Minami
    Hiroaki Masaie
    Jun Ishikawa
    International Journal of Hematology, 2016, 104 : 605 - 611
12345